Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Translational Data from OVATION 2 Trial Presented at AACR Special ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), , a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announced the publication of the mechanism ...

Imunon (IMNN) announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key ...

People with new-onset type 1 diabetes can achieve similar improvements in C-peptide levels with a 0.5 mg/kg antithymocyte ...

TNF-driven inflammatory arthritis, commonly accompanied by vitamin D deficiency. Here, we investigate the interaction between ...

Researchers evaluated the prevalence of low-level viremia and its influence on the risk for virologic failure in patients with HIV on antiretroviral therapy.

Type 1 diabetes remains a persistent health-care burden despite substantial advances in care. Its preclinical disease course ...

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine ...

Immuno-aging score and other hallmarks of aging were raised in patients during early stages of rheumatoid arthritis.

CD4-positive T cells are a subtype of lymphocyte. They are MHC class II-restricted and are important mediators of adaptive immunity. These cells are involved in both the induction and the restraint of ...